Sarda Proteins Falls to 52-Week Low of Rs.59.95 Amidst Challenging Market Conditions

Intraday Price Movements and Market Context

On 21 Nov 2025, Sarda Proteins opened with a gap down of 4.93%, setting the tone for a volatile trading session. The stock’s intraday high reached Rs.65, representing a 3.08% gain from the opening price, but it ultimately retreated to the day’s low of Rs.59.95. This closing price establishes the lowest level for the stock in the past 52 weeks, underscoring the challenges faced by the company in recent months.

Despite the setback, Sarda Proteins outperformed its sector peers by 3.41% during the trading day, indicating some relative resilience within the edible oil industry. However, the stock did not trade on one of the last 20 trading days, reflecting some irregularity in liquidity or trading interest.

Technical Indicators and Moving Averages

From a technical standpoint, the stock price currently sits below its short- and medium-term moving averages, including the 5-day, 20-day, 50-day, and 100-day averages. However, it remains above the 200-day moving average, suggesting that while recent momentum has been subdued, the longer-term trend has not yet fully shifted to a bearish stance. This mixed technical picture highlights the stock’s struggle to regain upward momentum amid prevailing market conditions.

Comparative Market Performance

Over the past year, Sarda Proteins has recorded a return of -39.73%, a stark contrast to the Sensex’s 10.68% gain during the same period. The Sensex itself opened lower on the day at 85,347.40, down 285.28 points or 0.33%, and was trading slightly below its 52-week high of 85,801.70 by 0.45%. The benchmark index continues to trade above its 50-day moving average, which remains above the 200-day moving average, signalling a generally bullish market environment that Sarda Proteins has not mirrored.

Financial Health and Profitability Metrics

Sarda Proteins’ financial indicators reveal areas of concern. The company has not declared results in the last six months, which contributes to uncertainty regarding its current financial position. Its ability to service debt is notably weak, with an average EBIT to interest ratio of 0.01, indicating minimal earnings before interest and taxes relative to interest obligations.

The company has reported losses, resulting in a negative return on equity (ROE). Additionally, the stock’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) have been negative, which adds to the risk profile of the stock compared to its historical valuations.

Long-Term and Recent Performance Trends

In addition to the one-year return of -39.73%, Sarda Proteins has underperformed the BSE500 index over the last three years, one year, and three months. Profitability has also shown a decline, with profits falling by 5% over the past year. These trends highlight challenges in both near-term and long-term performance relative to broader market benchmarks.

Sales Growth Amidst Challenges

Despite the overall subdued performance, the company reported a notable increase in net sales for the half-year period ending June 2025. Net sales reached ₹109.55 million, reflecting a growth rate of 18,127.29%. This sharp rise in sales contrasts with the stock’s price movement and profitability metrics, suggesting that revenue growth has not yet translated into improved earnings or market confidence.

Summary of Key Concerns

The stock’s decline to a 52-week low of Rs.59.95 reflects a combination of factors including weak financial results, negative profitability indicators, and underperformance relative to market indices. The absence of recent financial disclosures adds to the opacity surrounding the company’s current status. Furthermore, the low EBIT to interest ratio and negative EBITDA highlight ongoing financial pressures.

Market and Sector Context

Operating within the edible oil sector, Sarda Proteins faces competition and market dynamics that have influenced its stock price. While the sector itself has seen some relative stability, the company’s stock has not aligned with broader sectoral trends, as evidenced by its underperformance compared to sector peers and the Sensex.

Trading Patterns and Liquidity

The stock’s erratic trading pattern, including a day without trading in the last 20 sessions, may reflect liquidity constraints or investor caution. The gap down opening and intraday volatility further illustrate the unsettled nature of the stock’s price action.

Conclusion

Sarda Proteins’ fall to its 52-week low is a significant development that underscores the challenges faced by the company in maintaining market valuation amid financial and operational headwinds. The stock’s performance contrasts with the broader market’s positive momentum, highlighting the divergence between company-specific factors and general market trends.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →